Neuronal injury, dendritic loss and brain atrophy are non-limbic cortex, thalamus and white matter). Increased CSF quinolinic acid concentrations also correlated with frequent complications of infection with human immunodeficiency virus (HIV) type 1. Activated brain higher CSF HIV-1 RNA levels. In support of the specificity of these associations, blood levels of quinolinic acid were macrophages and microglia can release quinolinic acid, a neurotoxin and NMDA (N-methyl-D-aspartate) receptor unrelated to striatal and limbic volumes, and CSF levels of β 2 -microglobulin, a non-specific and non-excitotoxic agonist, which we hypothesize contributes to neuronal injury and cerebral volume loss. In the present crossmarker of immune activation, were unrelated to regional brain volume loss. These results are consistent with the sectional study of 94 HIV-1-infected patients, elevated CSF quinolinic acid concentrations correlated with worsening hypothesis that quinolinic acid accumulation in brain tissue contributes to atrophy in vulnerable brain regions brain atrophy, quantified by MRI, in regions vulnerable to excitotoxic injury (the striatum and limbic cortex) but in HIV infection and that virus replication is a significant driver of local quinolinic acid biosynthesis. not in regions relatively resistant to excitotoxicity (the
Introduction
In vivo brain imaging studies have demonstrated enlargement as white matter abnormalities in patients infected with the human immunodeficiency virus type 1 (HIV-1) (Post et al., of cortical sulcal and ventricular fluid spaces and volume loss in the striatum, temporal limbic cortex, white matter, 1988; Chrysikopoulos et al., 1990; Kieburtz et al., 1990; Dooneief et al., 1992; Jernigan et al., 1993) . Post-mortem anterior diencephalon and non-limbic cerebral cortex, as well studies have demonstrated dendritic and synaptic virus)-infected macaques have established that concentrations of quinolinic acid are elevated in the CSF, brain tissue and abnormalities that include substantial decreases in the complexity of dendritic arborization and loss of synapses blood (Heyes et al., , 1991a Achim et al., 1993; Brouwers et al., 1993; Gulevich et al., 1993; Sei et al., (Masliah et al., 1992a, b; Kerr et al., 1998) . Dendritic and synaptic damage in HIV infection are due, at least in 1995). Although the CSF compartment is distinct from that of brain tissue, the two compartments are nevertheless part, to excitotoxic injury from excessive glutamate receptor stimulation, as demonstrated in the post-mortem brain contiguous and CSF quinolinic acid levels have been shown to be highly representative of parenchymal values in terminal (Masliah et al., 1996; Epstein and Gelbard, 1999; Sardar et al., 1999) . Such loss of dendritic complexity as well as patients . Elevations in CSF quinolinic acid begin promptly after infection in association with virus neurodegeneration probably contributes to brain volume loss. Furthermore, dendritic simplification has been related to the entry into the CNS (Heyes et al., 1992a; Smith et al., 1995; Lane et al., 1996) and correlate with the severity of severity of cognitive disturbances (Masliah et al., 1997) . Volume reduction in the striatum and cerebral cortex are perceptual-motor slowing in the early stages of infection (Martin et al., 1992) . High CSF quinolinic acid concentrations associated with higher intensity of immunostaining for the HIV envelope protein gp41 (Heindel et al., 1994) .
are found in patients with the AIDS (acquired immunodeficiency syndrome) dementia complex and encephalitis, Collectively, these observations suggest that the presence of replicating virus within the CNS results in the anatomical and, importantly, correlate with the severity of neurological dysfunction in adults as well as measures of neurological neuronal pathology of HIV-associated neurological disease and is involved in the development of cognitive deficits.
developmental delays in children (Heyes et al., 1991a (Heyes et al., , c, 1998 Achim et al., 1993; Brouwers et al., 1993 ; Gulevich Neuronal injury and cell loss result from toxic mechanisms that are initiated and maintained by productive HIV infection et al., 1993; Sei et al., 1995) . It is important to note that, whereas a small percentage of quinolinic acid in CSF and in the CNS. It has been hypothesized that neurotoxicity is mediated directly by virus-coded toxins or indirectly by brain tissue can originate in blood, local tissue production is the predominant source during CNS inflammation and factors produced by brain cells, or by both mechanisms. Putative virus-coded toxins include gp120, gp41 and Tat encephalitis (Heyes and Morrison, 1997; . Attenuation of quinolinic acid biosynthesis by inhibition of protein (Brenneman et al., 1988; Adamson et al., 1999; Nath et al., 2000) . Host-coded mediators include the NMDA kynurenine pathway enzymes in macrophages and microglia is associated with reduced HIV-induced neurotoxicity in (N-methyl-D-aspartate) receptor agonist quinolinic acid, cytokines and nitric oxide Tyor et al., 1992;  susceptible neurones (Kerr et al., 1997; Chao et al., 2000) . We hypothesize that accumulations of quinolinic acid are Adamson et al., 1999; Chao et al., 2000) . The observations that HIV in the CNS is predominantly localized in monocyte/ involved in the pathogenesis of neuronal injury and brain atrophy in HIV-1-infected patients. The relationship of CSF macrophages and microglia and that macrophage-tropic isolates are associated with neurological disease to a greater quinolinic acid to measures of in vivo brain atrophy, however, has not been described. The rationale for the present study extent than T-cell-tropic isolates (Koyanagi et al., 1987) are consistent with the hypothesis that the production of of the relationships between CSF quinolinic acid concentrations and regional brain atrophy is as follows. First, neurotoxins from macrophages and microglia is an important component of neuropathogenesis (Heyes et al., , 1991a if quinolinic acid contributes to region-specific neuronal damage in HIV infection, then CSF quinolinic acid levels 1993; Giulian et al., 1990; Pulliam et al., 1991; Brew et al., 1995) .
should correlate with the degree of volume loss, as measured by quantitative MRI, particularly in vulnerable structuresQuinolinic acid is an endogenous neurotoxic metabolite of the tryptophan-kynurenine pathway and is produced in large the striatum and limbic cortex-but may or may not correlate in brain regions that are less sensitive to the neurotoxic quantities by activated macrophages and microglia (Heyes et al., 1992c (Heyes et al., , 1996 Espey et al., 1997; Kerr et al., 1997;  effects of quinolinic acid (the thalamus, non-limbic cortex and white matter). Secondly, in contrast to CSF quinolinic Chao et al., 2000) . Quinolinic acid activates the NMDA class of excitatory amino acid receptors to produce alterations in acid, serum quinolinic acid concentrations would not be related to volume loss in specific brain regions because the neuronal activity, neuronal damage and neurodegeneration (Stone, 1993) . Some brain regions and neuronal populations CNS is the predominant source of local quinolinic acid accumulations, and the two compartments may be metabolicare more vulnerable to the neurotoxic effect of quinolinic acid than others (Stone, 1993) . For example, infusions of ally independent. Thirdly, quinolinic acid production is probably stimulated both by HIV-1 replication and by non-specific nanomolar amounts of quinolinic acid locally into rat brain resulted in neuronal losses that were greatest in the striatum 'immune activation' in the CNS. We evaluated the relative roles of these stimuli by examining the correlation between and hippocampus and less marked in the lateral septal nuclei, substantia nigra, hypothalamus, cerebellum and non-limbic CSF quinolinic acid levels and levels of CSF HIV RNA and b 2 -microglobulin, a non-specific marker of activation of cerebral cortex (Schwarcz and Köhler, 1983 Details of the image analysis methods have been described informed consent was obtained from each participant prior previously (Jernigan et al., 1991c (Jernigan et al., , 1993 . Briefly, all image to his participation.
analyses were conducted blind to any subject characteristics. Details concerning the sources of participants and exclusion Each pixel location within a section of the imaged brain was criteria have been described previously (Heaton et al., 1995) .
classified on the basis of its signal values in both original Exclusion criteria included conditions that might increase images (TE ϭ 25 ms, TE ϭ 70 ms) as most resembling the likelihood of finding neuroradiological abnormalities CSF, grey matter, white matter or signal hyperintensity (tissue unrelated to HIV, such as head injury complicated by abnormality). Consistently identifiable landmark positions prolonged loss of consciousness; a history of a neurological and structural boundaries were then designated on the disorder such as epilepsy or encephalitis, metabolic or segmented images by trained image analysts. The processed endocrine diseases; cardiopulmonary disorders; current image data were transformed spatially to conform to a dependence on alcohol or other substances; or any diagnosis common anatomical coordinate system. Some regional of psychosis prior to HIV infection. Also excluded were boundaries were then defined relative to this coordinate patients with a clinical diagnosis of opportunistic disease scheme (i.e. stereotaxically). The volume for each structure of the brain, such as cryptococcal meningitis, progressive was estimated by summing the voxels in all images that multifocal leucoencephalopathy or toxoplasmosis.
included the designated structure.
Quantitation of brain regional volumes Clinical evaluations and CSF assays
Medical examinations and collections of blood and CSF were
The MRI volume measures were expressed as Z scores corrected for the normal variation in volume associated with performed within a period of 11 weeks. The average time between an MRI examination and lumbar puncture was age and cranial size (Jernigan et al., 1991c) . Adjustments were based on analyses conducted previously with a large 15 days; 50% of the sample was examined within 1 week of the MRI, 75% within 3 weeks and the remaining 25% group of normal controls that estimated the polynomial functions relating supratentorial cranium size and age to the between 3 and 11 weeks. Lumbar puncture was performed according to standard techniques, with 5-15 ml of CSF structural volumes. The adjusted structure volumes were expressed as deviations from the normative predicted values collected. Samples were aliquoted and stored at -70°C and subsequently assayed in batches for β 2 -microglobulin by divided by age-adjusted standard deviations, producing measures that were independent of brain size variation and enzyme immunoassay (Pharmacia Diagnostics, Fairfield, NJ, USA). β 2 -Microglobulin is associated with class I MHC age differences, and represent the degree to which a structure volume deviates from the expected size in the normal antigens on cell membranes, and is important both for the immunological recognition of self and for mounting cellular population. Since the volume measures represent estimated Z scores, they are expressed on roughly equivalent scales, immune responses (Flynn et al., 1992; Glas et al., 1992) . β 2 -Microglobulin elevation in CSF increases in concert with allowing direct comparisons between structures to be made. These age-and cranium size-corrected scores have been HIV disease progression (Lucey et al., 1991; Gulevich et al., 1993) . Unlike quinolinic acid, β 2 -microglobulin has no known shown to be useful in detecting region-specific brain changes associated with Alzheimer's dementia, Huntington's disease, neurotoxic effects. Quinolinic acid was quantified by electroncapture negative chemical ionization mass spectrometry with HIV encephalitis and alcoholism (Jernigan et al., 1991a (Jernigan et al., , b, 1993 . [ 2 H 3 ]quinolinic acid as internal standard (Heyes et al., 1992c . Test-retest reliability of the CSF quinolinic acid
The total brain, excluding the cerebellum and pons, was measured in five regions: the striatum, the thalamus, the measurement was determined by repeating the assay on different aliquots from the same lumbar puncture for 19 limbic cortex, the non-limbic cortex and the white matter.
The thalamus consisted of a single standardized volume participants chosen at random from the present sample. separated from the hypothalamic region on the basis of a following predictor variables: CSF quinolinic acid concentration, β 2 -microglobulin concentration and disease stereotaxically defined coronal plane. The limbic cortex included structures that constitute the septohippocampal severity (A, B or C). Correlation coefficients were also employed to assess the relationship between CSF quinolinic system (Gray and McNaughton, 1983) and was calculated as the average of two standardized volumes, the mesial temporal acid and CSF HIV RNA levels, as well as CSF quinolinic acid and CSF β 2 -microglobulin concentrations. Values presented lobe (the uncus, amygdala, hippocampus and parahippocampal gyrus) and the anterior diencephalic region (the are mean Ϯ standard deviation (SD) or standard error of the mean (SEM), as indicated. hypothalamus and the septal nuclei). The striatum volume comprised the combined volumes of the caudate nucleus, putamen and globus pallidus. The non-limbic cortex region comprised a single standardized volume of all cortical grey Results matter other than the limbic cortex as described above,
Clinical characteristics and measurements of
including the frontal, lateral temporal, parietal and occipital quinolinic acid and β 2 -microglobulin in CSF lobes. The total volume of white matter included any regions of white matter hyperintensity. The volume of the supra-
and serum
The distribution of participants in the CDC clinical categories tentorial cranium was estimated by summing supratentorial voxels (including CSF, signal hyperintensities, grey matter was as follows: Category A, 55% (n ϭ 52); Category B, 26% (n ϭ 25); Category C, 19% (n ϭ 17). Thirty participants and white matter) over all sections.
(32%) met the 1993 criteria for AIDS (i.e. individuals in Category C or with Ͻ200 CD4 T cells/µl). Table 1 provides data on CD4 T-cell counts, antiretroviral treatment status,
Statistical analyses
Because CSF quinolinic acid, serum quinolinic acid and CSF CSF and serum quinolinic acid concentrations and CSF β 2 -microglobulin concentrations for the participants at the time β 2 -microglobulin values were positively skewed in this cohort (Table 1 ), as in others described previously, raw values were of collection, grouped according to CDC disease stage.
In the cohort as a whole, participants had substantially transformed on a log 10 scale. A Shapiro-Wilk test confirmed that the distribution of the new values did not deviate from elevated CSF quinolinic acid levels, with a range of 5.7-485.0 nM (mean Ϯ SD, 58.7 Ϯ 67.9 nM) at the time of normality. Log 10 -transformed values were used in all analyses reported here.
their MRI scan. A previous study found that CSF quinolinic acid levels among HIV seronegative subjects of comparTo evaluate whether regional brain volume losses reflected overall disease progression or degree of immunosuppression, able ages ranged from 11.6 to 40.3 nM (18.4 Ϯ 3.4 nM) and another found that seronegative the relationships between volume loss and CDC (Centers for Disease Control) (1993) clinical class (A, B or C; A ϭ least subjects' CSF quinolinic acid levels ranged from 15 to 35 nM (22.1 Ϯ 2.1 nM) . CSF quinolinic acid advanced, C ϭ most advanced) were examined. CDC clinical class was analysed as a marker of disease severity with concentrations did not differ significantly among participants in CDC stages A, B and C. Serum quinolinic acid levels respect to a history of opportunistic diseases that reflect impaired cellular immunity. This was particularly important in the present cohort of HIV ϩ subjects (mean Ϯ SD, 1358 Ϯ 939 nM) exceeded those previously found in HIVbecause regional brain volumes have been shown to decrease with advancing stage of disease (Jernigan et al., 1993) .
controls of similar age (416 Ϯ 122 nM) (Halperin and Heyes, 1992) . However, among HIV ϩ subjects, the three CDC Bivariate correlation coefficients were calculated as Pearson r values. Multiple regression analyses were groups did not differ significantly from one another. The correlation between CSF and serum quinolinic acid concentraconducted to examine regional brain volume loss and the tions in the present group was ϩ0.42 (P Ͻ 0.001). The mean the volume of the striatum. In a parallel analysis for limbic CSF β 2 -microglobulin concentration was elevated compared volume, CSF quinolinic acid (partial F ϭ 5.7, P ϭ 0.02) but with normal values (Gulevich et al., 1993) and increased not CDC classification (partial F ϭ 1.2, P ϭ 0.27) contributed progressively according to CDC stage. The mean level of significantly to the model. Tests for interactions were per-CSF HIV RNA in this group was 2.3 Ϯ 1.5 log 10 copies per formed by splitting CSF quinolinic acid levels at the median, ml; 25% of samples had undetectable CSF HIV RNA levels. creating high and low CSF quinolinic acid categories and performing an ANOVA examining three predictors: CSF quinolinic acid (categorical), CDC class and the interaction
MRI analyses and prediction of regional brain
term CSF quinolinic acid ϫ CDC class. In both cases, the interaction terms were not significant. Thus, correlations volumes between CSF quinolinic acid and striatal and limbic atrophy Table 2 lists regional brain volumes according to the subjects' could not be explained simply by disease stage. CSF CDC disease stage classification. Regional volumes in the quinolinic acid levels were not significantly related to volumes present cohort as a whole were decreased relative to previin the non-limbic cortex, thalamus or white matter. Serum ously studied normative samples (Jernigan et al., 1993;  quinolinic acid concentrations did not correlate significantly Heindel et al., 1994) . As expected, more pronounced volume with volume loss in any brain region. loss was observed in the striatum and white matter of subjects CSF HIV RNA levels were not significantly related to with advanced clinical disease (CDC class C).
volume loss in any of the brain regions. A significant Correlations between MRI volumes, CSF and serum correlation was found, however, between HIV RNA CSF quinolinic acid concentrations and CSF β 2 -microglobulin concentrations and CSF quinolinic acid levels (r ϭ 0.37, concentrations are listed in Table 3 . CSF quinolinic acid P Ͻ 0.002). levels were correlated with the degree of volume loss in both Levels of CSF β 2 -microglobulin, a marker of CNS immune the striatum (r ϭ -0.22, P ϭ 0.03) and the limbic cortex activation, were not related to volume loss in any region. (r ϭ -0.24, P ϭ 0.02) (Fig. 1) . Notably, in a multiple
There was a significant correlation between CSF quinolinic regression analysis in which the volume of the striatum was acid levels and CSF β 2 -microglobulin (r ϭ 0.39, P Ͻ 0.0001). the outcome variable and CSF quinolinic acid and CDC Multiple regression analysis showed that β 2 -microglobulin classification (AIDS/CDC C versus non-AIDS/CDC A ϩ B)
and CSF viral RNA made independent contributions to the were predictor variables, CSF quinolinic acid levels (partial prediction of CSF quinolinic acid levels (F ϭ 6.9, P Ͻ 0.01 F ϭ 5.5, P ϭ 0.021) and CDC classification (partial F ϭ 5.1, P ϭ 0.026) made independent contributions to predicting and F ϭ 6.4, P Ͻ 0.01, respectively). microglobulin. Because β 2 -microglobulin is a marker of Discussion microglial activation (Morris and Esiri, 1998 ; Lidman et al., MRI-assessed brain atrophy in HIV-infected patients is linked 1999) that does not interact with glutamate receptors, these to productive HIV infection of the CNS, to both neuronal findings suggest that the volume loss was not simply a injury and neurodegeneration and to cognitive deficits consequence of non-specific immune activation, but rather (Masliah et al., 1992a (Masliah et al., , b, 1997 Heindel et al., 1994 ; Kerr was associated with excitotoxicity due to quinolinic acid. et al., 1998). There is currently considerable interest in the In order for quinolinic acid to be a significant contributor potential role of virus-coded and host-coded neurotoxins to brain atrophy in HIV-infected patients, the following must released from activated macrophages and microglia as be established: (i) that quinolinic acid levels are elevated mediators between the presence of HIV in the CNS and the prior to or coincident with the onset of atrophy in proportion occurrence of anatomical and functional neurological disease.
to the severity of atrophy rather than occurring after or as a Certain candidate mechanisms have been identified on the consequence of atrophy; (ii) that there is a link between basis of in vitro neurotoxicity, although their presence within productive HIV-1 infection and quinolinic acid production; the CNS and associations with quantitative measures of (iii) that quinolinic acid concentrations are elevated within functional and anatomical disease await confirmation. While susceptible brain regions; (iv) that quinolinic acid the cause of CNS disease is probably complex, with several concentrations at the synapse and at NMDA receptors achieve factors contributing to differing degrees at different stages neuroactive levels; and (v) that elevated CSF quinolinic of disease, the present study focused on a hypothesisacid levels correlate with elevated quinolinic acid levels at driven approach to evaluate the contribution of one potential the synapse. candidate. The results showed that increased CSF quinolinic A history of previously elevated CSF quinolinic acid levels acid levels were associated with regional volume loss in in the present cohort of patients was not available. However, brain structures that are particularly sensitive to the in other early stage HIV-infected patients, highly significant excitotoxic effects of quinolinic acid, namely the striatum correlations have been observed between CSF quinolinic acid and limbic cortex (Table 2) . Because CSF quinolinic acid levels at a given time point with values measured 6, 12 or levels were associated with atrophy independent of CDC 18 months later (Heyes et al., 1992a) . We have now replicated stage, and because serum quinolinic acid concentrations did this finding with a separate cohort from the HNRC (R. J. not correlate with regional cerebral volume measures, it is Ellis and M. P. Heyes, unpublished observation). Thus, a unlikely that CSF quinolinic acid concentrations and brain single measure of CSF quinolinic acid levels is an index of atrophy simply reflect disease stage or a generalized systemic values over a prolonged period of time. The association process. Furthermore, regional cerebral volume measures were not correlated with CSF concentrations of β 2 -between CSF quinolinic acid levels and the severity of atrophy during the early stages of neurological disease Schwarcz, 1989) . Giulian and colleagues reported the death of rat hippocampus neurones following exposure to a indicates that elevations in CSF quinolinic acid levels occur either prior to or contemporaneously with the development concentration of quinolinic acid of 100 nM for 24 h (Giulian et al., 1990) . Brew and colleagues found degeneration of of brain atrophy. The elevations in CSF quinolinic acid in the present study cannot, however, be attributed to or be a human cortical neurones in response to 0.5-1.2 µM quinolinic acid (Kerr et al., 1997 (Kerr et al., , 1998 . Clearly, the quinolinic acid consequence of brain atrophy itself because patients with other conditions causing regional brain atrophy, such as levels reached in post-mortem brain and CSF of HIVinfected patients exceed this neurotoxic threshold by a Huntington's disease and Alzheimer's disease, do not have elevated CSF or brain parenchymal quinolinic acid substantial margin. Quinolinic acid causes neurotoxicity via activation of concentrations (Heyes et al., 1991b (Heyes et al., , 1992c Krieger et al., 1994; Mouradian et al., 1989) .
NMDA receptors localized on the neuronal cell membrane and accessed via the extracellular fluid space (Stone, 1993) . The correlation between CSF quinolinic acid levels and CSF HIV RNA levels supports the hypothesis that viral It was not possible to measure quinolinic acid concentrations directly in the brain tissue or extracellular fluid space of the replication is a significant driving force in local quinolinic acid production. The observation that cultures of HIVpatients in the present study. However, CSF is anatomically contiguous with the extracellular fluid space and CSF infected macrophages and microglia release large quantities of quinolinic acid, particularly with macrophage-tropic HIV quinolinic acid concentrations are proportional to those in the extracellular fluid space of the brain (Beagles et al., strains and wild-type virus isolated from demented patients (Brew et al., 1995; Kerr et al., 1997; Chao et al., 2000) , is 1998). In this context, highly significant correlations and a gradient in concentrations are found between quinolinic acid consistent with this hypothesis. The correlation between CSF quinolinic acid levels and CSF β 2 -microglobulin indicates levels in brain tissue homogenates, the extracellular fluid and CSF in HIV-infected patients and in animal models of that non-specific CNS immune activation is an additional stimulus. Such non-specific immune activation may occur as CNS-localized inflammation (Blight et al., 1995; ). These observations demonstrate that locally a result of HIV-1 replication as well as CNS damage (Blight et al., 1995) . In accordance with these interpretations, large synthesized quinolinic acid enters the extracellular fluid and eventually the CSF in a quantitative relationship (Beagles accumulations of quinolinic acid in brain tissue have been reported in HIV-infected patients with encephalitis caused et al., 1998). We interpret the elevations in CSF quinolinic acid in the present study as indicative of production and either by HIV or other inflammatory processes (Sei et al., 1995) . Interestingly, MRI atrophy did not correlate with accumulation of quinolinic acid in brain tissue and entry into the extracellular fluid space, although the anatomical either CSF viral RNA or β 2 -microglobulin concentrations (Table 3) . Therefore, the correlation between CSF quinolinic localization and magnitude of such increases could not be determined. Whereas the concentrations of quinolic acid in acid levels and the degree of brain atrophy may reflect the position of quinolinic acid as a more proximal mediator of CSF in the present study averaged Ͻ100 nM (Table 1) and were lower than those found in terminal disease (Heyes et al. , neuronal injury than HIV replication or non-specific immune activation. Furthermore, the specificity of the relationships 1998), it has been shown previously that CSF quinolinic acid measurements underestimate parenchymal values in HIV and between CSF quinolinic acid and brain atrophy in particularly vulnerable regions is emphasized by the finding that CSF SIV infection by up to one order of magnitude . Also, local accumulations of quinolinic acid in the quinolinic acid levels were not predictive of damage to the non-limbic cortex, thalamus or white matter, regions that brain reflect local synthesis, probably by activated macrophages and microglia, where substantially larger have relatively low sensitivity to quinolinic acid neurotoxicity.
In post-mortem studies of HIV-infected subjects, elevated concentrations than those predicted by CSF measures occur (Beagles et al., 1998; ). An additional quinolinic acid concentrations are seen in CSF, basal ganglia, cerebral cortex and cortical white matter (Achim et al., 1993;  factor that facilitates excitotoxicity is the duration of exposure (Whetsell and Schwarcz, 1989; Kerr Heyes et al., 1998) . These increased concentrations were, on average, more than 100-fold greater than the concentrations et al., 1998). The available evidence is that increases in CNS quinolinic acid levels in HIV-1 infection begin promptly after found in neurologically normal controls and patients with Huntington's disease or Alzheimer's disease (Mouradian infection and are sustained throughout the course of disease (Heyes et al., 1991a (Heyes et al., , 1992a Martin et al., 1992; Brouwers et al., 1989; Heyes et al., 1991b Heyes et al., , 1992c Krieger et al., 1994) . The concentrations in HIV-infected patients averaged et al., 1993; Smith et al., 1995; Lane et al., 1996) . Three factors are of relevance with respect to atrophy of Ͼ20.0 µM (20.0 pmol/g) in brain tissue and 3.79 µM in CSF. Three independent studies of susceptible neurones in the basal ganglia and limbic cortex. First, these two regions are particularly sensitive to the excitotoxic effects of culture have found quinolinic acid-induced neurotoxicity in the range of 0.1-100 µM. Specifically, Schwarcz and quinolinic acid (Stone, 1993) . Other regions are less sensitive, and atrophy in areas such as the thalamus and cerebral cortex colleagues reported dendritic injury and neurodegeneration when organotypic corticostriatal neurones were exposed to may also be related to additional neurotoxic mediators. Measurement of such factors was beyond the scope of the 0.1-1.0 µM quinolinic acid for 7 weeks (Whetsell and injury from excessive glutamate receptor stimulation, as demonstrated in the post-mortem brain (Masliah et al., 1996;  Brew BJ, Corbeil J, Pemberton L, Evans L, Saito K, Penny R, et al. Epstein and Gelbard, 1999; Sardar et al., 1999) . Because of receptors or inhibiting events downstream in the neurotoxic Science 1990; 248: 364-7. cascade, including calcium influx (Dreyer et al., 1990) , glutathione depletion and oxidative damage. We also propose 
